Novel vasopressin V1A and V2 antagonist (Conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia

被引：0
|
作者：
Verbalis, JG
Bisaha, JG
Smith, N
机构：
[1] Yamanouchi Pharma Amer Inc, Paramus, NJ USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
来源：
CIRCULATION | 2004年 / 110卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3346
引用
收藏
页码：723 / 723
页数：1
相关论文
共 50 条
  • [21] Conivaptan, a novel arginine vasopressin antagonist, produced aquaresis and increased serum sodium concentration in patients with euvolemic and hypervolemic hyponatremia.
    Verbalis, JG
    Ghali, JK
    Gross, P
    Long, WA
    Smith, N
    PHARMACOTHERAPY, 2005, 25 (10): : 1447 - 1447
  • [22] Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise
    Balling, Louise
    Wolsk, Emil
    Hassager, Christian
    Boesgaard, Soren
    Goldsmith, Steven R.
    Gustafsson, Finn
    AMERICAN HEART JOURNAL, 2018, 203 : 101 - 104
  • [23] Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors
    Mouillac, B
    Phalipou, S
    Cotte, N
    Balestre, MN
    Hibert, M
    Manning, M
    Barberis, C
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 359 - 361
  • [24] Pharmacotherapy for hyponatraemia in heart failure: effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan (YM087) administered orally
    Abraham, W
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    Nelson, C
    Bakker-Arkema, RG
    EUROPEAN HEART JOURNAL, 2000, 21 : 345 - 345
  • [25] Pharmacological characterization of RWJ-676070, a dual vasopressin V1A/V2 receptor antagonist
    Gunnet, Joseph W.
    Wines, Pamela
    Xiang, Min
    Rybczynski, Philip
    Andrade-Gordon, Patricia
    de Garavilla, Lawrence
    Parry, Tom J.
    Cheung, Wai-man
    Minor, Lisa
    Demarest, Keith T.
    Maryanoff, Bruce E.
    Damiano, Bruce P.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 590 (1-3) : 333 - 342
  • [26] Haemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist, in patients with advanced heart failure
    Udelson, J
    Smith, WB
    Hendrix, G
    Painchaud, C
    Ghazzi, MM
    Thomas, I
    Ghali, J
    Selaru, P
    Pressler, M
    Konstam, M
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [27] Hemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, MM
    Thomas, I
    Ghali, JK
    Selaru, P
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2000, 102 (18) : 593 - 593
  • [28] IDENTIFICATION OF VASOPRESSIN V1A AND V2 RECEPTORS IN THE RENAL MICROCIRCULATION
    PARK, F
    MATTSON, DL
    ALKAYED, NJ
    FRANCHINI, KG
    ROMAN, RJ
    COWLEY, AW
    FASEB JOURNAL, 1995, 9 (03): : A264 - A264
  • [29] Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia:: A randomized trial
    Gines, Pere
    Wong, Florence
    Watson, Hugh
    Milutinovic, Slobodan
    del Arbol, Luis Ruiz
    Olteanu, Dan
    HEPATOLOGY, 2008, 48 (01) : 204 - 213
  • [30] Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia
    Madias, Nicolaos E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (02) : 184 - 187
12345